a DES Son opinion
My own opinion is that DES caused intersexed development in the DES sons by blocking testicular testosterone production. DES is a potent chemical castration agent that for many years the treatment of choice for hormone-sensitive prostate cancer. Just 3mg of DES per day is enough to fully chemically castrate an adult man; the starting dose as a miscarriage treatment was 5mg per day (and often went much higher during the later stages of the pregnancy). It’s a not widely appreciated fact, but male development isn’t driven directly by genes, but instead by hormones (primarily testosterone) produced in the testicles of a male fetus. Given the ability DES has to block testosterone production, it’s no surprise that many DES sons are physically and/or psychologically intersexed. The surprising thing is that there’s so little public awareness of it!
If the problem is just one of testosterone production being suppressed during the critical time sexual development was taking place, then I don’t see any reason for there to be any long term genetic effect or 3rd generation effects. However, one thought that’s occured to me is that DES daughters often have a great deal of difficulty getting pregnant and carrying the pregnancy to term, which puts them at vastly increased risk of medical intervention – and potentially being given hormonal medication during the pregnancy. If one of these hormonal treatments for miscarriage (DES) can cause problems with intersexed development, then the likelihood is that others can too. There’s one drug in particular called hydroxyprogesterone caproate, which is in widespread current use to prevent miscarriages and premature births, and is being given in doses which I’m sure would have some serious gender-bending effects if you were to give the same dose to an adult man.
In short, although DES was phased out 40 years ago, there’s plenty of other sex hormone derivatives still finding their way inside pregnant women and potentially causing many of the same problems. That’s why I’ve been trying so hard to get people to take me seriously, and see whether there’s a link between exposure to these drugs before birth and endocrine and intersex-related problems later in life!
A post comment by Hugh Easton
Posted by DES Daughter on 18/05/2013
DES Action NSW is asking pharmacists to display the historic DES posters
In a joint project with students from Macquarie University, DES Action NSW is asking pharmacists to display the historic DES posters at their scripts-in counters to prompt people to find out about problems associated with exposure to diethylstilboestrol (DES).
So far 75 Sydney pharmacies have agreed to take part in the project but according to DES Action NSW co-ordinator Carol Devine the participation needs to be more widespread.
Read A ’50s ad carries a powerful message
by Emma Swain, May 15, 2013
Posted by DES Daughter on 18/05/2013
DES side-effects on bones
” Estrogens have important effects on bone turnover in both humans and experimental animals models. Moreover, the decreased level of estrogen after menopause appears to be one of the key factors in determining postmenopausal osteoporosis. The presence of estrogen receptor in both osteoblasts and osteoclasts has suggested a direct role of these steroid hormones on bone tissue. Thus, this tissue is now regarded as a specific estrogen target tissue. Exposure to estrogens during various stages of development has been shown to irreversibly influence responsive target organs. We have recently shown that transient developmental neonatal exposure (days 1-5 of life) of female mice to estrogen resulted in an augmented bone density in the adult animals. The aim of the present study was to evaluate whether short-term modification of maternal estrogen levels during pregnancy would induce changes in the skeleton of the developing fetuses and to identify any long-term alterations that may occur. Pregnant mice were injected with varying doses (0.1-100 micrograms/kg maternal BW) of the synthetic estrogen diethylstilbestrol (DES) from day 9-16 of pregnancy. Offspring were weaned at 21 days of age, and effects on bone tissue of the female mice were evaluated in adulthood (6-9 months of age). Prenatal DES treatment(s) did not significantly affect BW. However, a dose-dependent increase in bone mass, both in the trabecular and cortical compartments, was observed in the prenatal DES-exposed female offspring. Furthermore, long bones of DES-exposed females were shorter than controls. Normal skeletal mineralization accompanied these changes in the bone tissue, as shown by a parallel increase in skeletal calcium content. Double tetracycline labeling performed in 6-month-old DES-exposed animals showed an increase in mineral apposition rate in adult DES-exposed mice as compared with untreated control animals, although no significant difference in the circulating estrogen levels was found in animals of this age. Experiments were then performed to evaluate whether perturbation of the estrogen surge at puberty in these diethylstilbestrol (DES)-exposed mice could reverse the observed changes. Femur length was chosen as a marker of potential estrogenic effect. Prepubertal ovariectomy of the prenatally DES-treated animals could only partially reverse the effects observed in the skeleton of the DES-treated animals. Further experiments were performed to evaluate whether these changes could have occurred in utero. CD-1 pregnant female mice were injected with DES (100 micrograms/kg maternal BW) from days 9-15 of gestation. On day 16 of gestation, fetuses were examined and stained by a standard Alizarin Red S and Alcian Blue procedure to visualize calcified and uncalcified skeletal tissue. Estrogen treatment induced an increase in the amount of calcified skeleton as compared with untreated controls and also a decrease in the length of long bones, strongly suggesting a change in both endochondral ossification and endosteal and periosteal bone formation. In summary, these data show, for the first time, that alterations in the maternal estrogenic levels during pregnancy can influence early phases of fetal bone tissue development and subsequently result in permanent changes in the skeleton. Finally, the effect of this short-term estrogen treatment can be seen in the fetal skeleton, suggesting an estrogen-imprinting effect on bone cell-programming in fetal life because treatment effects on bone cell turnover can be observed later in adult life. “
Abstract, NCBI Endocrinology, 1996 May – Full text here
Posted by DES Daughter on 17/05/2013
DES tablets manufactured by Eli Lilly
Did your mum take DES?
This DiEthyl-Stilbestrol 5 mg drug bottle image could help you ask and find out…
Diaporama and DES Drugs Information
See more DES drugs photo set on flickr®
If you already have a flickr® account,
add us as a contact
Email your photos to email@example.com
with a short description and title
Posted by DES Daughter on 16/05/2013
Estrogens like DES permanently disrupt the hormonal mechanisms regulating body weight
A new study found that endocrine disruptors cause mice to grow obese and suffer liver disease through at least three generations.
This confirms the 2005 NIEHS Study where DES appears to permanently disrupt the hormonal mechanisms regulating body weight in mice – (see Elizabeth Grossman’s “Chemicals May Play Role in Rise in Obesity“).
The common thread is that the most important time for exposure appears to be in utero and in childhood. Should doctors do more to warn pregnant women about certain chemicals?
Read Warnings From a Flabby Mouse, by Nicholas D. Kristof
The NewYorkTimes, January 2013
Posted by DES Daughter on 13/05/2013
Non, nous n’avons pas encore tiré toutes les leçons de l’histoire du DES
Hhorages a rassemblé le témoignage de 1240 familles dont 1734 enfants ont été exposés au DES. Parmi eux, plus de la moitié (949) sont atteints de problèmes psychiatriques seuls, 464 ont en plus des troubles somatiques et 190 des troubles somatiques seuls. Une autre étude sur 529 familles, réalisée par l’association et publiée dans le journal Médecine et Longévité en 2011, constate que sur 740 enfants ayant subi une exposition prénatale au DES, 405 ont des troubles psychiatriques.
En savoir plus:
Posted by DES Daughter on 12/05/2013
Téléchargez le manuel sur les effets nocifs des médicaments
La revue indépendante Prescrire a mis en ligne, en libre accès, un guide des effets indésirables des médicaments, destiné aux futurs professionnels de la santé, ainsi qu’à la formation continue. Deux rubriques sont consacrées au Distilbene DES. Vous pouvez télécharger le manuel complet ou commander la version imprimée.
En savoir plus:
Posted by DES Daughter on 08/05/2013
DES Daughters are 82% more likely to develop breast cancer after age 40 …
The number of UK women under aged 50 diagnosed with breast cancer has topped 10,000 for the first time. While it’s not clear why the rates are rising in this age group, survival rates among women under 50 are improving thanks to research and increased awareness of the disease.
DES Daughters are 82% more likely to develop breast cancer after age 40 … Could the fact that Breast cancer in women under 50 is becoming more common be explained by the fact that the majority of DES Daughters are only reaching their 40′s now … ??? Just wondering?
More on Breast Cancer Symptoms via CancerResearchUK.org
Download CancerResearchUK Breast Cancer Quick Guide
Posted by DES Daughter on 07/05/2013
The Pill of Truth
If there was one pill that I wish the FDA would approve it would be this one …
Read The Truth about Diethylstilbestrol
by John Krueger
May 9, 2012
Posted by DES Daughter on 07/05/2013
Judith Barrow self-published Silent Trauma
Find out why Judith Barrow, author of Silent Trauma, a wonderful book written to draw attention about the DES drug tragedy, self-published her novel.
I did approach my own publishers and four others. The reasons for the rejections were twofold. One was that “they wouldn’t be able to sell ‘issue–led’ novels”. And two, I was told, was the worry of being sued by the drug companies.
Read How to Use Self-Publishing To Promote a Charity or Cause – with Guest Author Judith Barrow
by Debbie Young
Related post: Silent Trauma by Judith Barrow on Flickr
Posted by DES Daughter on 06/05/2013
Distilbène, les Recherches se poursuivent
Il était naturel pour la Mutualité Française de s’associer de cette manière à une étude de santé publique consacrée aux effets indésirables d’un médicament, un thème sur lequel elle est particulièrement investie”, explique la Dre Annabel Dunbavand, conseillère médicale à la FNMF, qui rappelle que la santé des femmes fait partie des dossiers prioritaires du mouvement mutualiste pour l’année 2013.
La Mutualité Française soutient l’étude d’une association de défense des victimes du Distilbène®. Cette enquête vise à évaluer le lien entre l’exposition à cette hormone pendant la grossesse et le risque de développer un cancer du sein.
Lisez Cancer du sein : les filles du Distilbène® sont-elles plus exposées? par Sabine Dreyfus, 26/03/2013
Posted by DES Daughter on 05/05/2013